Last updated: June 18, 2026
What is the Janssen v. Evenus case about (1:20-cv-09369) and which patents are asserted?
No case-specific identifiers are provided beyond the caption and docket number. A litigation summary for a Hatch-Waxman case requires at minimum the asserted U.S. patent numbers (and typically the specific Orange Book-listed product and ANDA applicant), plus the date of the complaint and service, and the patents’ expiration and asserted claim scope. Those details are not available in the prompt.
What Orange Book drug and ANDA product are implicated?
The prompt does not state the Orange Book NDA/Reference Listed Drug, the dosage form (tablet, capsule, injectable, patch), or the ANDA submission details (applicant name, ANDA number, paragraph IV notice date).
What type of infringement claims are pleaded?
A complete summary needs the infringement theory (literal infringement vs. equivalents), the asserted claims per patent, and whether the complaint also pleads induced/contributory infringement. Those allegations are not included.
What are the procedural posture checkpoints?
A litigation analysis depends on whether the case is in the pleading stage, the claim construction stage, trial, or post-trial/settlement. The prompt provides no history such as scheduling order dates, Markman hearing dates, Daubert rulings, summary judgment motions, or final judgment entries.
What litigation timeline matters for Paragraph IV cases in D.N.J. (1:20-cv-09369)?
A credible timeline must include at least: complaint filing date, Paragraph IV notice date, answer date, any motion to dismiss, claim construction schedule, any preliminary injunction requests, and final disposition or settlement date. None of these dates are in the prompt.
When are the key deadlines under Hatch-Waxman triggered?
For Paragraph IV cases, timelines turn on statutory triggers tied to the notice letter and ANDA approval status. The prompt does not include the notice date or the NDA/ANDA approval state.
How strong is the patent estate for Janssen in this dispute: validity, enforceability, and infringement?
Strength analysis requires the exact asserted patents and the content of Janssen’s infringement position and Evenus’s defenses and counterarguments (invalidity grounds, noninfringement theories, inequitable conduct allegations if any, written description/enablement challenges, and prosecution history arguments). None of that information is provided.
What common invalidity arguments are typically litigated here?
Typical Hatch-Waxman invalidity defenses include anticipation/obviousness under §§102/103, obviousness combinations, indefiniteness, and lack of written description or enablement under §112. The prompt provides no grounds asserted in this specific docket.
What noninfringement and design-around positions are used by ANDA filers?
Noninfringement analysis requires claim charts or at least the asserted product composition and how Evenus’s ANDA differs from the patent limitations. The prompt provides no ANDA formulation, manufacturing process, or parameter differences.
What filings and rulings decide the case outcome for (1:20-cv-09369)?
A litigation summary normally consolidates court decisions such as: motions to dismiss, claim construction order, summary judgment rulings, bench or jury verdicts, and any appellate activity. The prompt does not include any rulings, docket entries, or disposition details.
Was there a Markman claim construction order?
An analysis depends on construed claim terms and their impact on infringement and validity. No claim construction information is provided.
Was there a settlement or consent judgment?
A settlement analysis requires the entry date, terms affecting launch (eg, agreed-at-risk launch prohibition, stipulated injunction, license terms, payment amount if any, and duration), and the effect on remaining asserted patents. None of this is present.
Did Evenus get to market, and what is the generic entry risk (1:20-cv-09369)?
Generic entry risk requires: (1) whether the ANDA was approved, (2) whether an injunction was issued, (3) whether the court lifted any injunction, (4) whether exclusivities or other listed patents remain in force, and (5) the timing of allowable launch triggers. The prompt contains none of these commercial/regulatory outcomes.
What is the regulatory status: ANDA approval and Orange Book “carve-out” effects?
Orange Book status and any authorized generic or tentative approval require Orange Book and FDA action data. Not provided.
What is the practical launch date exposure?
Exposure analysis ties launch to the latest expiration among the asserted patents and any exclusivity periods. No asserted patents or expiration dates are provided.
Which parties and counsel are involved, and who controls enforcement?
A full case dossier includes party roles (plaintiff NDA holder vs. patent owner), additional defendants if any, and assignment of asserted patents. The prompt provides only the plaintiff name and the defendant company, with no patent owner list, related entities, or counsel identifiers.
Are there related cases in D.N.J. or other districts?
Parallel Hatch-Waxman litigations are often filed against multiple ANDA filers or under related patents. The prompt does not identify related dockets.
How does this Janssen v. Evenus litigation compare with other Janssen patent challenges in the same timeframe?
Comparison requires the same Janssen product/patent set and other litigations with similar procedural outcomes. The prompt gives only one docket number.
Comparative outcome metrics used in similar cases
Standard metrics include: proportion ending in settlement vs. judgment, time to resolution, rate of injunction, and whether courts sustained invalidity or found noninfringement. None of this can be computed without asserted patents and outcomes.
What manufacturing or IP barriers typically arise from this fact pattern?
Barriers depend on the specific technology claimed (e.g., polymorphs, compositions, process steps, dosage form, method of use). The prompt does not identify the claimed invention.
Key takeaways
- The provided information is insufficient to produce a complete litigation summary and legal analysis for Janssen Products, L.P. v. Evenus Pharmaceuticals Laboratories Inc. (1:20-cv-09369).
- A Hatch-Waxman litigation analysis requires asserted patent numbers, Orange Book reference drug, ANDA/par IV dates, claim constructions, court rulings, and final disposition or settlement terms. Those core case-specific inputs are not included.
FAQs
- What information is required to summarize a Paragraph IV Hatch-Waxman case docket accurately?
- How do claim construction rulings typically drive infringement outcomes in ANDA patent suits?
- What settlement terms most often determine whether an ANDA filer can launch at risk?
- How is “generic entry risk” assessed using Orange Book status and statutory exclusivities?
- What are the most common validity defenses raised by generic ANDA filers under §§102/103 and §112?
References
No sources cited.
